Efficient Production of a Bioactive Bevacizumab monoclonal antibody using the 2A self-cleavage peptide in transgenic rice callus

Frontiers in Plant Science

Volumn 7, Issue AUG2016, 2016, Pages

  Chen, Lei ^a,b   Yang, Xiaoyu ^c   Luo, Da ^a   Yu, Weichang ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHENZHEN UNIVERSITY   (China)

Author keywords

2A self cleavage peptide; Bevacizumab; Monoclonal antibody (mAb); Plant made antibody; Plant transformation; Rice

Indexed keywords

EID: 84984638432     PISSN: None     EISSN: 1664462X     Source Type: Journal    
DOI: 10.3389/fpls.2016.01156     Document Type: Article

References (91)

1. Ali, S. A., McHayleh, W. M., Ahmad, A., Sehgal, R., Braffet, M., Rahman, M., et al. (2008). Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J. Neurosurg. 109, 268-272. doi: 10.3171/JNS/2008/109/8/0268
2. Atkins, J. F., Wills, N. M., Loughran, G., Wu, C. Y., Parsawar, K., Ryan, M. D., et al. (2007). A case for "StopGo": reprogramming translation to augment codon meaning of GGN by promoting unconventional termination (Stop) after addition of glycine and then allowing continued translation (Go). RNA 13, 803-810. doi: 10.1261/rna.487907
3. Barta, A., Sommergruber, K., Thompson, D., Hartmuth, K., Matzke, M. A., and Matzke, A. J. (1986). The expression of a nopaline synthase - human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue. Plant Mol. Biol. 6, 347-357. doi: 10.1007/BF00034942
4. Bellmunt, J. (2007). Current treatment in advanced renal cell carcinoma (RCC): impact of targeted therapies in the management of RCC. Eur. Urol. Suppl. 6, 484-491. doi: 10.1016/j.eursup.2007.01.018
5. Castilho, A., and Steinkellner, H. (2012). Glyco-engineering in plants to produce human-like N-glycan structures. Biotechnol. J. 7, 1088-1098. doi: 10.1002/biot.201200032
6. Castilho, A., Windwarder, M., Gattinger, P., Mach, L., Strasser, R., Altmann, F., et al. (2014). Proteolytic and N-glycan processing of human alpha1-antitrypsin expressed in Nicotiana benthamiana. Plant Physiol. 166, 1839-1851. doi: 10.1104/pp.114.250720
7. Chng, J., Wang, T., Nian, R., Lau, A., Hoi, K. M., Ho, S. C., et al. (2015). Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. MAbs 7, 403-412. doi: 10.1080/19420862.2015. 1008351
8. Chu, C. C., Wang, C. C., Sun, C. S., Hsu, K. C., Yen, K. C., Chu, C. Y., et al. (1975). Establishment of an efficient medium for anther culture of rice through comparative experimentation on the nitrogen source. Sci. Sin. 13, 659-668.
9. Corbin, J. M., Hashimoto, B. I., Karuppanan, K., Kyser, Z. R., Wu, L., Roberts, B. A., et al. (2016). Semicontinuous bioreactor production of recombinant butyrylcholinesterase in transgenic rice cell suspension cultures. Front. Plant Sci. 7:412. doi: 10.3389/fpls.2016.00412
10. de Felipe, P., Luke, G. A., Hughes, L. E., Gani, D., Halpin, C., and Ryan, M. D. (2006). E unum pluribus: multiple proteins from a self-processing polyprotein. Trends Biotechnol. 24, 68-75. doi: 10.1016/j.tibtech.2005.12.006
11. De Muynck, B., Navarre, C., and Boutry, M. (2010). Production of antibodies in plants: status after twenty years. Plant Biotechnol. J. 8, 529-563. doi: 10.1111/j.1467-7652.2009.00494.x
12. Decker, E. L., and Reski, R. (2008). Current achievements in the production of complex biopharmaceuticals with moss bioreactors. Bioprocess Biosyst. Eng. 31, 3-9. doi: 10.1007/s00449-007-0151-y
13. Desai, P. N., Shrivastava, N., and Padh, H. (2010). Production of heterologous proteins in plants: strategies for optimal expression. Biotechnol. Adv. 28, 427-435. doi: 10.1016/j.biotechadv.2010.01.005
14. Domigan, C. K., Ziyad, S., and Iruela-Arispe, M. L. (2015). Canonical and noncanonical vascular endothelial growth factor pathways: new developments in biology and signal transduction. Arterioscler. Thromb. Vasc. Biol. 35, 30-39. doi: 10.1161/ATVBAHA.114.303215
15. Donnelly, M. L., Hughes, L. E., Luke, G., Mendoza, H., ten Dam, E., Gani, D., et al. (2001). The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J. Gen. Virol. 82, 1027-1041. doi: 10.1099/0022-1317-82-5-1027
16. Doran, P. M. (2006). Foreign protein degradation and instability in plants and plant tissue cultures. Trends Biotechnol. 24, 426-432. doi: 10.1016/j.tibtech.2006.06.012
17. Doronina, V. A., Wu, C., de Felipe, P., Sachs, M. S., Ryan, M. D., and Brown, J. D. (2008). Site-specific release of nascent chains from ribosomes at a sense codon. Mol. Cell. Biol. 28, 4227-4239. doi: 10.1128/MCB.00421-08
18. Ellis, L. M., and Hicklin, D. J. (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591. doi: 10.1038/nrc2403
19. Fallot, S., Ben Naya, R., Hieblot, C., Mondon, P., Lacazette, E., Bouayadi, K., et al. (2009). Alternative-splicing-based bicistronic vectors for ratio-controlled protein expression and application to recombinant antibody production. Nucleic Acids Res. 37:e134. doi: 10.1093/nar/gkp716
20. Fang, J., Qian, J. J., Yi, S., Harding, T. C., Tu, G. H., VanRoey, M., et al. (2005). Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23, 584-590. doi: 10.1038/nbt1087
21. Ferrara, N., Hillan, K. J., and Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333, 328-335. doi: 10.1016/j.bbrc.2005.05.132
22. Franklin, S. E., and Mayfield, S. P. (2005). Recent developments in the production of human therapeutic proteins in eukaryotic algae. Expert Opin. Biol. Ther. 5, 225-235. doi: 10.1517/14712598.5.2.225
23. Frenzel, A., Hust, M., and Schirrmann, T. (2013). Expression of recombinant antibodies. Front. Immunol. 4:217. doi: 10.3389/fimmu.2013.00217
24. Fujiwara, Y., Yang, L., Takaiwa, F., and Sekikawa, K. (2016). Expression and purification of recombinant mouse interleukin-4 and -6 from transgenic rice seeds. Mol. Biotechnol. 58, 223-231. doi: 10.1007/s12033-016-9920-7
25. Gardner, A. M., Aviel, S., and Argon, Y. (1993). Rapid degradation of an unassembled immunoglobulin light chain is mediated by a serine protease and occurs in a pre-Golgi compartment. J. Biol. Chem. 268, 25940-25947.
26. Gerber, H. P., and Ferrara, N. (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65, 671-680.
27. Giantonio, B. J. (2006). Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings. Semin. Oncol. 33, S15-S18. doi: 10.1053/j.seminoncol.2006.08.003
28. Girard, L. S., Fabis, M. J., Bastin, M., Courtois, D., Petiard, V., and Koprowski, H. (2006). Expression of a human anti-rabies virus monoclonal antibody in tobacco cell culture. Biochem. Biophys. Res. Commun. 345, 602-607. doi: 10.1016/j.bbrc.2006.03.219
29. Goel, H. L., and Mercurio, A. M. (2013). VEGF targets the tumour cell. Nat. Rev. Cancer 13, 871-882. doi: 10.1038/nrc3627
30. Gomord, V., Sourrouille, C., Fitchette, A. C., Bardor, M., Pagny, S., Lerouge, P., et al. (2004). Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge. Plant Biotechnol. J. 2, 83-100. doi: 10.1111/j.1467- 7652.2004.00062.x
31. Gonzalez, R., Andrews, B. A., and Asenjo, J. A. (2002). Kinetic model of BiP- and PDI mediated protein folding and assembly. J. Theor. Biol. 214, 529-537. doi: 10.1006/jtbi.2001.2478
32. Hayashi, H., Arao, T., Matsumoto, K., Kimura, H., Togashi, Y., Hirashima, Y., et al. (2014). Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. Oncotarget 5, 2588-2595. doi: 10.18632/oncotarget.1811
33. He, Y., Ning, T., Xie, T., Qiu, Q., Zhang, L., Sun, Y., et al. (2011). Large-scale production of functional human serum albumin from transgenic rice seeds. Proc. Natl. Acad. Sci. U.S.A. 108, 19078-19083. doi: 10.1073/pnas.1109736108
34. Hehle, V. K., Paul, M. J., Roberts, V. A., van Dolleweerd, C. J., and Ma, J. K. (2016). Site-targeted mutagenesis for stabilization of recombinant monoclonal antibody expressed in tobacco (Nicotiana tabacum) plants. FASEB J. 30, 1590-1598. doi: 10.1096/fj.15-283226
35. Hennecke, M., Kwissa, M., Metzger, K., Oumard, A., Kroger, A., Schirmbeck, R., et al. (2001). Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res. 29, 3327-3334. doi: 10.1093/nar/29.16.3327
36. Hiatt, A., Cafferkey, R., and Bowdish, K. (1989). Production of antibodies in transgenic plants. Nature 342, 76-78. doi: 10.1038/342076a0
37. Ho, S. C., Bardor, M., Feng, H., Mariati I, Tong, Y. W., Song, Z., et al. (2012). IRES-mediated Tricistronic vectors for enhancing generation of high monoclonal antibody expressing CHO cell lines. J. Biotechnol. 157, 130-139. doi: 10.1016/j.jbiotec.2011.09.023
38. Ho, S. C., Bardor, M., Li, B., Lee, J. J., Song, Z., Tong, Y. W., et al. (2013a). Comparison of internal ribosome entry site (IRES) and Furin-2A (F2A) for monoclonal antibody expression level and quality in CHO cells. PLoS ONE 8:e63247. doi: 10.1371/journal.pone.0063247
39. Ho, S. C., Koh, E. Y., van Beers, M., Mueller, M., Wan, C., Teo, G., et al. (2013b). Control of IgG LC:HC ratio in stably transfected CHO cells and study of the impact on expression, aggregation, glycosylation and conformational stability. J. Biotechnol. 165, 157-166. doi: 10.1016/j.jbiotec.2013.03.019
40. Huang, T. K., and McDonald, K. A. (2012). Bioreactor systems for in vitro production of foreign proteins using plant cell cultures. Biotechnol. Adv. 30, 398-409. doi: 10.1016/j.biotechadv.2011.07.016
41. Jiang, Z., Huang, Y., and Sharfstein, S. T. (2006). Regulation of recombinant monoclonal antibody production in chinese hamster ovary cells: a comparative study of gene copy number, mRNA level, and protein expression. Biotechnol. Prog. 22, 313-318. doi: 10.1021/bp0501524
42. Kathuria, S., Sriraman, R., Nath, R., Sack, M., Pal, R., Artsaenko, O., et al. (2002). Efficacy of plant-produced recombinant antibodies against HCG. Hum. Reprod. 17, 2054-2061. doi: 10.1093/humrep/17.8.2054
43. Kim, T. G., Baek, M. Y., Lee, E. K., Kwon, T. H., and Yang, M. S. (2008). Expression of human growth hormone in transgenic rice cell suspension culture. Plant Cell Rep. 27, 885-891. doi: 10.1007/s00299-008-0514-0
44. Ko, K. (2014). Expression of recombinant vaccines and antibodies in plants. Monoclon. Antib. Immunodiagn. Immunother. 33, 192-198. doi: 10.1089/mab.2014.0049
45. Kolarich, D., Altmann, F., and Sunderasan, E. (2006). Structural analysis of the glycoprotein allergen Hev b 4 from natural rubber latex by mass spectrometry. Biochim. Biophys. Acta 1760, 715-720. doi: 10.1016/j.bbagen.2005.11.012
46. Kolotilin, I., Topp, E., Cox, E., Devriendt, B., Conrad, U., Joensuu, J., et al. (2015). Plant-based solutions for veterinary immunotherapeutics and prophylactics. Vet. Res. 45, 117. doi: 10.1186/s13567-014-0117-4
47. Kuo, Y. C., Tan, C. C., Ku, J. T., Hsu, W. C., Su, S. C., Lu, C. A., et al. (2013). Improving pharmaceutical protein production in Oryza sativa. Int. J. Mol. Sci. 14, 8719-8739. doi: 10.3390/ijms14058719
48. Kurogochi, M., Mori, M., Osumi, K., Tojino, M., Sugawara, S., Takashima, S., et al. (2015). Glycoengineered monoclonal antibodies with homogeneous glycan (M3, G0, G2, and A2) using a chemoenzymatic approach have different affinities for FcγRIIIa and variable antibody-dependent cellular cytotoxicity activities. PLoS ONE 10:e0132848. doi: 10.1371/journal.pone. 0132848
49. Law, R. D., Russell, D. A., Thompson, L. C., Schroeder, S. C., Middle, C. M., Tremaine, M. T., et al. (2006). Biochemical limitations to high-level expression of humanized monoclonal antibodies in transgenic maize seed endosperm. Biochim. Biophys. Acta 1760, 1434-1444. doi: 10.1016/j.bbagen.2006.05.006
50. Lee, C. J., Seth, G., Tsukuda, J., and Hamilton, R. W. (2009). A clone screening method using mRNA levels to determine specific productivity and product quality for monoclonal antibodies. Biotechnol. Bioeng. 102, 1107-1118. doi: 10.1002/bit.22126
51. Liu, J. F., and Matulonis, U. A. (2015). Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 16, 876-878. doi: 10.1016/S1470-2045(15)00064-9
52. Madeira, L. M., Szeto, T. H., Henquet, M., Raven, N., Runions, J., Huddleston, J., et al. (2015). High-yield production of a human monoclonal IgG by rhizosecretion in hydroponic tobacco cultures. Plant Biotechnol. J. 14, 615-624. doi: 10.1111/pbi.12407
53. Makino, T., Skretas, G., Kang, T. H., and Georgiou, G. (2011). Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies. Metab. Eng. 13, 241-251. doi: 10.1016/j.ymben.2010.11.002
54. Mason, W. P. (2015). Bevacizumab in recurrent glioblastoma: five informative patient scenarios. Can. J. Neurol. Sci. 42, 149-156. doi: 10.1017/cjn.2015.21
55. Merlin, M., Gecchele, E., Capaldi, S., Pezzotti, M., and Avesani, L. (2014). Comparative evaluation of recombinant protein production in different biofactories: the green perspective. Biomed Res. Int. 2014, 136419. doi: 10.1155/2014/136419
56. Minskaia, E., Nicholson, J., and Ryan, M. D. (2013). Optimisation of the foot-and- mouth disease virus 2A co-expression system for biomedical applications. BMC Biotechnol. 13:67. doi: 10.1186/1472-6750-13-67
57. Minskaia, E., and Ryan, M. D. (2013). Protein coexpression using FMDV 2A: effect of "Linker" residues. Biomed Res. Int. 2013, 291730. doi: 10.1155/2013/291730
58. Ni, Y., and Chen, R. (2009). Extracellular recombinant protein production from Escherichia coli. Biotechnol. Lett. 31, 1661-1670. doi: 10.1007/s10529-009- 0077-3
59. Nishimura, A., Aichi, I., and Matsuoka, M. (2006). A protocol for Agrobacterium- mediated transformation in rice. Nat. Protoc. 1, 2796-2802. doi: 10.1038/nprot.2006.469
60. Pal, S. K., Hu, A., Chang, M., and Figlin, R. A. (2014). Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions. Clin. Adv. Hematol. Oncol. 12, 90-99.
61. Presta, L. G., Chen, H., O’Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L., et al. (1997). Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599.
62. Reusch, D., and Tejada, M. L. (2015). Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 25, 1325-1334. doi: 10.1093/glycob/cwv065
63. Rodriguez, M., Ramirez, N. I., Ayala, M., Freyre, F., Perez, L., Triguero, A., et al. (2005). Transient expression in tobacco leaves of an aglycosylated recombinant antibody against the epidermal growth factor receptor. Biotechnol. Bioeng. 89, 188-194. doi: 10.1002/bit.20333
64. Ryan, M. D., King, A. M., and Thomas, G. P. (1991). Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J. Gen. Virol. 72(Pt 11), 2727-2732. doi: 10.1099/0022-1317-72-11- 2727
65. Sainsbury, F., Lavoie, P. O., D’Aoust, M. A., Vezina, L. P., and Lomonossoff, G. P. (2008). Expression of multiple proteins using full-length and deleted versions of cowpea mosaic virus RNA-2. Plant Biotechnol. J. 6, 82-92. doi: 10.1111/j.1467-7652.2007.00303.x
66. Saint-Jore-Dupas, C., Faye, L., and Gomord, V. (2007). From planta to pharma with glycosylation in the toolbox. Trends Biotechnol. 25, 317-323. doi: 10.1016/j.tibtech.2007.04.008
67. Schillberg, S., Raven, N., Fischer, R., Twyman, R. M., and Schiermeyer, A. (2013). Molecular farming of pharmaceutical proteins using plant suspension cell and tissue cultures. Curr. Pharm. Res. 19, 5531-5542. doi: 10.2174/1381612811319310008
68. Schlatter, S., Stansfield, S. H., Dinnis, D. M., Racher, A. J., Birch, J. R., and James, D. C. (2005). On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol. Prog. 21, 122-133. doi: 10.1021/bp049780w
69. Sharma, P., Yan, F., Doronina, V. A., Escuin-Ordinas, H., Ryan, M. D., and Brown, J. D. (2011). 2A peptides provide distinct solutions to driving stop-carry on translational recoding. Nucleic Acids Res. 40, 3143-3151. doi: 10.1093/nar/gkr1176
70. Shih, S. M., and Doran, P. M. (2009). Foreign protein production using plant cell and organ cultures: advantages and limitations. Biotechnol. Adv. 27, 1036-1042. doi: 10.1016/j.biotechadv.2009.05.009
71. Sil, B., and Jha, S. (2014). Plants: the future pharmaceutical factory. Am. J. Plant Sci. 5, 319-327. doi: 10.4236/ajps.2014_53044
72. Smolenska, L., Roberts, I. M., Learmonth, D., Porter, A. J., Harris, W. J., Wilson, T. M., et al. (1998). Production of a functional single chain antibody attached to the surface of a plant virus. FEBS Lett. 441, 379-382. doi: 10.1016/S0014- 5793(98)01586-5
73. Spadiut, O., Capone, S., Krainer, F., Glieder, A., and Herwig, C. (2013). Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol. 32, 54-60. doi: 10.1016/j.tibtech.2013.10.002
74. Stoger, E., Ma, J. K., Fischer, R., and Christou, P. (2005). Sowing the seeds of success: pharmaceutical proteins from plants. Curr. Opin. Biotechnol. 16, 167-173. doi: 10.1016/j.copbio.2005.01.005
75. Strasser, R., Altmann, F., and Steinkellner, H. (2014). Controlled glycosylation of plant-produced recombinant proteins. Curr. Opin. Biotechnol. 30, 95-100. doi: 10.1016/j.copbio.2014.06.008
76. Strasser, R., Stadlmann, J., Schahs, M., Stiegler, G., Quendler, H., Mach, L., et al. (2008). Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6, 392-402. doi: 10.1111/j.1467- 7652.2008.00330.x
77. Tekoah, Y., Shulman, A., Kizhner, T., Ruderfer, I., Fux, L., Nataf, Y., et al. (2015). Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience. Plant Biotechnol. J. 13, 1199-1208. doi: 10.1111/pbi.12428
78. Tewari, K. S., Sill, M. W., Long, H. J. III, Penson, R. T., Huang, H., Ramondetta, L. M., et al. (2014). Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370, 734-743. doi: 10.1056/NEJMoa1309748
79. Thie, H., Schirrmann, T., Paschke, M., Dubel, S., and Hust, M. (2008). SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. N. Biotechnol. 25, 49-54. doi: 10.1016/j.nbt.2008.01.001
80. Tonini, G., Imperatori, M., Vincenzi, B., Frezza, A. M., and Santini, D. (2013). Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J. Exp. Clin. Cancer Res. 32, 92. doi: 10.1186/1756-9966-32-92
81. Van Droogenbroeck, B., Cao, J., Stadlmann, J., Altmann, F., Colanesi, S., Hillmer, S., et al. (2007). Aberrant localization and underglycosylation of highly accumulating single-chain Fv-Fc antibodies in transgenic Arabidopsis seeds. Proc. Natl. Acad. Sci. U.S.A. 104, 1430-1435. doi: 10.1073/pnas.0609997104
82. Vanhove, M., Usherwood, Y. K., and Hendershot, L. M. (2001). Unassembled Ig heavy chains do not cycle from BiP in vivo but require light chains to trigger their release. Immunity 15, 105-114. doi: 10.1016/S1074-7613(01)00163-7
83. Vaquero, C., Sack, M., Chandler, J., Drossard, J., Schuster, F., Monecke, M., et al. (1999). Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves. Proc. Natl. Acad. Sci. U.S.A. 96, 11128-11133. doi: 10.1073/pnas.96.20.11128
84. Villani, M. E., Morgun, B., Brunetti, P., Marusic, C., Lombardi, R., Pisoni, I., et al. (2009). Plant pharming of a full-sized, tumour-targeting antibody using different expression strategies. Plant Biotechnol. J. 7, 59-72. doi: 10.1111/j.1467- 7652.2008.00371.x
85. Voss, A., Niersbach, M., Hain, R., Hirsch, H. J., Yu, C. L., and Kreuzaler, F. (1995). Reduced virus infectivity in N. tabacum secreting a TMV-specific full-size antibody. Mol. Breed. 1, 39-50. doi: 10.1007/BF01682088
86. Wang, Y., Fei, D., Vanderlaan, M., and Song, A. (2004). Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7, 335-345. doi: 10.1007/s10456-004-8272-2
87. Weigel, D., and Glazebrook, J. (2006). Transformation of Agrobacterium using the freeze-thaw method. CSH Protoc. 2006:pdb.prot4666. doi: 10.1101/pdb.prot 4666
88. Xu, J., Dolan, M. C., Medrano, G., Cramer, C. L., and Weathers, P. J. (2012). Green factory: plants as bioproduction platforms for recombinant proteins. Biotechnol. Adv. 30, 1171-1184. doi: 10.1016/j.biotechadv.2011.08.020
89. Xu, J., Ge, X., and Dolan, M. C. (2011). Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures. Biotechnol. Adv. 29, 278-299. doi: 10.1016/j.biotechadv.2011.01.002
90. Yang, X., Li, J., Chen, L., Louzada, E. S., He, J., and Yu, W. (2015). Stable mitotic inheritance of rice minichromosomes in cell suspension cultures. Plant Cell Rep. 34, 929-941. doi: 10.1007/s00299-015-1755-3
91. Zeitlin, L., Pettitt, J., Scully, C., Bohorova, N., Kim, D., Pauly, M., et al. (2011). Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. U.S.A. 108, 20690-20694. doi: 10.1073/pnas.1108360108